Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 02:45 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics får klartecken att starta den andra delen av en klinisk fas 2-studie i kronisk njursjukdom med anemi

STOCKHOLM, 4 november, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics har fått regulatoriskt godkännande att inleda den andra delen av...
November 04, 2025 02:45 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics receives approval for second part of phase 2 study in chronic kidney disease with anemia

STOCKHOLM, SWEDEN November 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the...
November 03, 2025 05:59 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag BOOST Pharma tar in Sound Bioventures i investerarsyndikatet genom en investering om 34 miljoner kronor

STOCKHOLM, SVERIGE 3 november 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget BOOST Pharma har tagit in 34 miljoner kronor, genom ett trancherat...
November 03, 2025 05:59 ET | Source: Karolinska Development AB (publ)

Karolinska Development portfolio company BOOST Pharma adds Sound Bioventures to investor syndicate with SEK 34 million investment

Stockholm, Sweden – November 3, 2025 – Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has raised a SEK 34 million investment structured as a...
October 31, 2025 05:55 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag BOOST Pharma presenterar positiva långtidsdata för sin cellterapi mot Osteogenesis imperfecta

STOCKHOLM, 31 oktober 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget BOOST Pharma har presenterat nya långtidsdata från den kliniska fas 1/2-studien BOOSTB4...
October 31, 2025 05:55 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company BOOST Pharma presents positive long-term data for its cell-based treatment of Osteogenesis imperfecta

STOCKHOLM, SWEDEN, October 31, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has presented new long-term data from the BOOSTB4 phase...
October 28, 2025 06:06 ET | Source: Karolinska Development AB (publ)

Karolinska Development investerar 7,5 miljoner SEK för att stödja BOOST Pharmas fortsatta utveckling av BT-101 mot klinisk fas 3

STOCKHOLM, SVERIGE - 28 oktober 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att bolaget har deltagit med sin pro rata-andel om 7,5 miljoner kronor i portföljbolaget BOOST...
October 28, 2025 06:06 ET | Source: Karolinska Development AB (publ)

Karolinska Development invests SEK 7.5 million to support BOOST Pharma’s continued development of BT-101 towards Phase 3

Stockholm, Sweden – October 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that it has exercised its pro rata participation of SEK 7.5 million in BOOST Pharma’s latest...
October 24, 2025 02:45 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag SVF Vaccines presenterar positiva data från en preklinisk studie med SVF-001 inom kronisk hepatit B och D

STOCKHOLM, 24 oktober 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget SVF Vaccines har presenterat positiva resultat från en preklinisk studie med bolagets...
October 24, 2025 02:45 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company SVF Vaccines presents positive data from a preclinical study of SVF-001 in chronic hepatitis B and D

STOCKHOLM, Sweden, October 24, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented positive results from a preclinical study of its...